RxDoctor Payments Data

Praneetha Thulasi, MD

Ophthalmology · Saint Louis, MONPI 1740546696

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,446 of the $5,348 with a category attached, or 83.1%. 7 manufacturers reported payments, led by GSK at 54.7% of the total. Reporting peaked in 2020 at $2,925 and has fallen 99.4% since, to $18 in 2025.

$5,348in general payments, 2019–2025

Across 13 payments — averaging $411.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Sanofi$2K
  • Alcon$578
  • Amgen$125
  • Oyster Point Pharma, Inc.$101
  • Glaukos Corporation$80
  • plus $18 from 1 others
$59,484in research payments, 2019–2025

Across 19 payments — averaging $3130.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$59K

What the payments were for

  • Consulting fees$4,44683%
  • Food & beverage$90217%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,348 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$220,931
Medicare patients
486
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj14$393,125
Prednisolone Acetate749$35,447
RestasisCyclosporine46$33,778
MoxifloxacinMoxifloxacin Hcl567$15,012
Fluorometholone150$14,292
Loteprednol Etabonate66$13,057
ValacyclovirValacyclovir Hcl162$12,795
Cyclosporine21$12,343
XiidraLifitegrast16$11,038
LotemaxLoteprednol Etabonate25$10,173
CombiganBrimonidine Tartrate/Timolol11$9,128
CequaCyclosporine12$7,934
Alphagan PBrimonidine Tartrate11$6,588
Lotemax SmLoteprednol Etabonate16$5,649
Ketorolac Tromethamine147$3,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$18$11,03816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →